KALARIS THERAPEUTICS, INC. Earnings Per Share (Diluted)
KALARIS THERAPEUTICS, INC. (KLRS) reported Earnings Per Share (Diluted) of -$0.48 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.48.
- KALARIS THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.46.
- KALARIS THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.64.
- KALARIS THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-06-30 was -$0.61.
- KALARIS THERAPEUTICS, INC. earnings per share, diluted for fiscal 2025 was -$2.85.
- KALARIS THERAPEUTICS, INC. earnings per share, diluted for fiscal 2024 was -$51.77.
- KALARIS THERAPEUTICS, INC. earnings per share, diluted for fiscal 2023 was -$42.09.
- KALARIS THERAPEUTICS, INC. earnings per share, diluted for fiscal 2022 was -$2.20.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.48 10-Q · filed 2026-08-11 | -$0.94 10-Q · filed 2026-08-11 | ||||||
| 2026-03-31 | -$0.46 10-Q · filed 2026-05-12 | |||||||
| 2025-12-31 | -$2.85 10-K · filed 2026-03-17 | |||||||
| 2025-09-30 | -$0.64 10-Q · filed 2025-11-12 | -$2.41 10-Q · filed 2025-11-12 | ||||||
| 2025-06-30 | -$0.61 10-Q · filed 2026-08-11 | -$1.89 10-Q · filed 2026-08-11 | ||||||
| 2025-03-31 | -$2.52 10-Q · filed 2026-05-12 | |||||||
| 2024-12-31 | -$13.50 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$16.56 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$21.19 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$51.77 10-K · filed 2026-03-17 | -$11.73 10-K · filed 2025-03-07 | |||
| 2024-09-30 | -$28.16 10-Q · filed 2025-11-12 | -$0.04 10-Q · filed 2024-11-12 | -$7.62 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$35.44 10-Q · filed 2025-11-12 | -$0.35 10-Q · filed 2024-11-12 | $1.43 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||
| 2024-06-30 | -$4.26 10-Q · filed 2025-08-13 | -$0.05 10-Q · filed 2024-08-09 | -$6.87 10-Q · filed 2025-08-13 | -$0.32 10-Q · filed 2024-08-09 | $1.02 derived: net income ÷ weighted average shares · filed 2025-08-13 | $3.35 derived: net income ÷ weighted average shares · filed 2025-08-13 | ||
| 2024-03-31 | -$2.60 10-Q · filed 2025-05-14 | -$0.26 10-Q · filed 2024-05-13 | $0.64 derived: net income ÷ weighted average shares · filed 2025-05-14 | $2.39 derived: net income ÷ weighted average shares · filed 2025-05-14 | $9.69 derived: net income ÷ weighted average shares · filed 2025-05-14 | |||
| 2023-12-31 | $0.21 derived: net income ÷ weighted average shares · filed 2025-03-07 | $1.22 derived: net income ÷ weighted average shares · filed 2025-03-07 | $5.94 derived: net income ÷ weighted average shares · filed 2025-03-07 | -$42.09 10-K · filed 2025-03-07 | -$1.83 10-K · filed 2024-03-15 | |||
| 2023-09-30 | -$0.39 10-Q · filed 2024-11-12 | -$0.86 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$1.30 10-Q · filed 2024-11-12 | -$1.71 derived: net income ÷ weighted average shares · filed 2024-11-12 | ||||
| 2023-06-30 | -$0.48 10-Q · filed 2024-08-09 | -$0.92 10-Q · filed 2024-08-09 | -$1.33 derived: net income ÷ weighted average shares · filed 2024-08-09 | -$1.82 derived: net income ÷ weighted average shares · filed 2024-08-09 | ||||
| 2023-03-31 | -$0.44 10-Q · filed 2024-05-13 | -$0.85 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$1.34 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$1.98 derived: net income ÷ weighted average shares · filed 2024-05-13 | ||||
| 2022-12-31 | -$0.41 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.90 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$1.55 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$2.20 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | -$0.50 10-Q · filed 2023-11-02 | -$1.16 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$1.83 10-Q · filed 2023-11-02 | -$2.72 derived: net income ÷ weighted average shares · filed 2023-11-02 | ||||
| 2022-06-30 | -$0.69 10-Q · filed 2023-08-03 | -$1.38 10-Q · filed 2023-08-03 | -$2.29 derived: net income ÷ weighted average shares · filed 2023-08-03 | -$3.01 derived: net income ÷ weighted average shares · filed 2023-08-03 | ||||
| 2022-03-31 | -$0.69 10-Q · filed 2023-05-04 | -$1.60 derived: net income ÷ weighted average shares · filed 2023-05-04 | -$2.32 derived: net income ÷ weighted average shares · filed 2023-05-04 | -$2.93 derived: net income ÷ weighted average shares · filed 2023-05-04 | ||||
| 2021-12-31 | -$0.91 derived: net income ÷ weighted average shares · filed 2023-02-15 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-02-15 | -$2.24 derived: net income ÷ weighted average shares · filed 2023-02-15 | -$2.74 10-K · filed 2023-02-15 | ||||
| 2021-09-30 | -$0.72 10-Q · filed 2022-11-03 | -$1.33 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.82 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | -$0.60 10-Q · filed 2022-08-04 | -$1.10 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |